KalVista Licenses Pendopharm Rights to Commercialize HAE Therapy in Canada

Rare Daily Staff

KalVista Pharmaceuticals said it granted Pendopharm, a division of Pharmascience, the exclusive rights to manage the regulatory approval process and commercialization of its experimental therapy for hereditary angioedema, sebetralstat, in Canada.

Financial terms of the agreement were not disclosed.

Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein, leading to uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. All currently approved on-demand treatment options require either intravenous or subcutaneous administration.

Sebetralstat is an oral plasma kallikrein inhibitor. KalVista has filed multiple regulatory applications seeking approval of sebetralstat as the first oral, on-demand treatment for HAE in individuals aged 12 and older. The company is also investigating its use in children aged 2 to 11.

“This partnership supports our broader goal of making sebetralstat available globally, as the first and only oral on-demand treatment that has the potential to transform HAE care,” said Ben Palleiko, CEO of KalVista.

Photo: Ben Palleiko, CEO of KalVista